stockrow
Friday 6 November 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
65.55
0.12
−0.18%
Follow PTCT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 8.64 |
+8 more quarters Free account |
P/S ratio |
4.68 | 6.71 | 6.80 | 3.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 13.62 | |
P/Operating CF |
(213.65) | 52.44 | (95.22) | (176.27) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.30 | 7.39 | 7.67 | 3.87 | |
EV/EBITDA |
31.91 | 45.79 | 0.00 | 7.53 | |
EV/Operating CF |
583.73 | (244.38) | (29.11) | 9.41 | |
EV/FCF |
(23.62) | (24.83) | (13.14) | 15.10 | |
Quick Ratio |
3.05 | 3.20 | 2.29 | 2.20 | |
Current Ratio |
3.27 | 3.39 | 2.44 | 2.35 | |
Net Debt/EBITDA |
19.10 | 4.27 | 12.55 | (10.33) | |
Debt/Assets |
88.59% | 89.60% | 91.11% | 89.62% | |
Debt/Equity |
(14.86) | (17.61) | (14.49) | (12.65) | |
Asset Turnover |
0.40 | 0.34 | 0.30 | 0.75 | |
Operating CF/Net income |
0.49 | 1.55 | 21.02 | 0.25 | |
Capex/Depreciation |
(0.49) | (0.64) | (0.11) | (0.29) | |
Interest Coverage |
0.55 | 3.07 | 0.92 | (1.29) | |
Research and Development Expense of Revenue |
29.44% | 27.50% | 37.01% | 80.84% | |
Selling, General and Administrative Expense of Revenue |
22.38% | 22.36% | 31.62% | 58.83% | |
Intangible Assets out of Total Assets |
0.16 | 0.15 | 0.16 | 0.16 | |
Share Based Compensation of Revenue |
6.66% | 6.46% | 8.59% | 11.25% | |
Graham Net Nets |
(0.16) | (0.12) | (0.14) | (0.14) | |
Graham Number |
8.21 | 4.69 | 10.71 | 0.00 | |
Earnings Yield |
(2.02%) | (0.60%) | (3.42%) | 11.57% | |
Free Cash Flow Yield |
(4.79%) | (4.43%) | (8.59%) | 7.34% | |
Revenue per Share |
4.29 | 4.34 | 3.30 | 2.07 | |
Operating CF per Share |
(0.30) | 1.56 | (0.72) | (0.43) | |
Capex per Share |
(0.07) | (0.09) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(0.38) | 1.47 | (0.73) | (0.46) | |
Cash per Share |
25.49 | 26.85 | 22.93 | 24.46 | |
Shareholders Equity per Share |
(2.29) | (1.99) | (2.19) | (2.58) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.29) | (1.99) | (2.19) | (2.58) | |
Free Cash Flow |
(31.33) | 121.97 | (60.39) | (36.65) | |
Working Capital |
1,761.71 | 1,846.29 | 1,330.40 | 1,305.52 | |
Capital Expenditures |
(6.02) | (7.14) | (1.35) | (2.37) | |
Net Current Asset Value |
(861.14) | (798.48) | (795.57) | (830.13) | |
EV/EBIT |
41.45 | 59.35 | 0.00 | 7.72 | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 | |
Price to Operating Income |
36.61 | 53.91 | 0.00 | 6.97 | |
| Other line items | |||||
Average Receivables |
220.57 | 217.59 | 215.21 | 170.09 | |
Average Payables |
371.98 | 360.60 | 315.43 | 342.78 | |
Average Inventory |
81.01 | 62.71 | 48.62 | 51.42 | |
Average Assets |
2,925.71 | 2,942.32 | 2,762.25 | 2,301.90 | |
Average Common Equity |
(173.48) | (185.95) | (183.11) | (651.69) |
Columns are period end dates · fundamentals updated 6 Nov 2026